drugset / Trial / NCT01506414

Summary

The purpose of this study is to determine whether Recombinant Human Thrombopoietin (rh-TPO) in combination with Rituximab are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).

Timeline

Start
2009-06
Primary completion
2013-08
Completion
2013-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 100 mg Intravenous
Subject recombinant human thrombopoietin Protein / enzyme biologic 1 ug/kg Subcutaneous